[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Lonza’s first-half core EBITDA gains 16.5%

07/22/2022

Less than a minute

2022.07.22 08:18

Lonza's first-half core EBITDA gains 16.5%
FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann

By Ludwig Burger

(Reuters) – Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.

First-half core earnings – adjusted for interest, tax, depreciation and amortisation – (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday. That was above an analyst consensus of about 940 million.

Source

07/22/2022

Less than a minute